These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21233022)

  • 21. B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.
    Brandl C; Ortler S; Herrmann T; Cardell S; Lutz MB; Wiendl H
    PLoS One; 2010 May; 5(5):e10800. PubMed ID: 20520738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Harnessing invariant NKT cells in vaccination strategies.
    Cerundolo V; Silk JD; Masri SH; Salio M
    Nat Rev Immunol; 2009 Jan; 9(1):28-38. PubMed ID: 19079136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.
    Webb TJ; Carey GB; East JE; Sun W; Bollino DR; Kimball AS; Brutkiewicz RR
    Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27297969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
    Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
    Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
    Seino K; Motohashi S; Fujisawa T; Nakayama T; Taniguchi M
    Cancer Sci; 2006 Sep; 97(9):807-12. PubMed ID: 16805854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
    Sun W; Subrahmanyam PB; East JE; Webb TJ
    J Interferon Cytokine Res; 2012 Nov; 32(11):505-16. PubMed ID: 23050947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte.
    Rhost S; Löfbom L; Rynmark BM; Pei B; Månsson JE; Teneberg S; Blomqvist M; Cardell SL
    Eur J Immunol; 2012 Nov; 42(11):2851-60. PubMed ID: 22777932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
    Favreau M; Vanderkerken K; Elewaut D; Venken K; Menu E
    Oncotarget; 2016 Apr; 7(17):23128-40. PubMed ID: 26895468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amelioration of NK cell function driven by Vα24
    Iyoda T; Yamasaki S; Hidaka M; Kawano F; Abe Y; Suzuki K; Kadowaki N; Shimizu K; Fujii SI
    Clin Immunol; 2018 Feb; 187():76-84. PubMed ID: 29061445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-talk between cd1d-restricted nkt cells and γδ cells in t regulatory cell response.
    Liu W; Huber SA
    Virol J; 2011 Jan; 8():32. PubMed ID: 21255407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.
    Dasgupta S; Kumar V
    Immunogenetics; 2016 Aug; 68(8):665-76. PubMed ID: 27405300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice.
    Wang HX; Li WJ; Hou CL; Lai S; Zhang YL; Tian C; Yang H; Du J; Li HH
    Cardiovasc Res; 2019 Jan; 115(1):83-93. PubMed ID: 29939225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing NKT cell ligands as vaccine adjuvants.
    Carreño LJ; Kharkwal SS; Porcelli SA
    Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Killing activity of human umbilical cord blood-derived TCRValpha24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells.
    Hagihara M; Gansuvd B; Ueda Y; Tsuchiya T; Masui A; Tazume K; Inoue H; Kato S; Hotta T
    Cancer Immunol Immunother; 2002 Mar; 51(1):1-8. PubMed ID: 11845254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower cytokine secretion ex vivo by natural killer T cells in HIV-infected individuals is associated with higher CD161 expression.
    Snyder-Cappione JE; Loo CP; Carvalho KI; Kuylenstierna C; Deeks SG; Hecht FM; Rosenberg MG; Sandberg JK; Kallas EG; Nixon DF
    AIDS; 2009 Sep; 23(15):1965-70. PubMed ID: 19590406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
    Li X; Huang J; Kawamura A; Funakoshi R; Porcelli SA; Tsuji M
    Vaccine; 2017 May; 35(24):3171-3177. PubMed ID: 28483194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
    Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
    Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.
    Li Y; Zhao C; Liu J; Lu Z; Lu M; Gu J; Liu R
    Oncol Rep; 2019 May; 41(5):2679-2688. PubMed ID: 30864713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.
    Lameris R; de Bruin RC; van Bergen En Henegouwen PM; Verheul HM; Zweegman S; de Gruijl TD; van der Vliet HJ
    Immunology; 2016 Sep; 149(1):111-21. PubMed ID: 27312006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.